본문 바로가기
대메뉴 바로가기
KAIST
Newsletter Vol.28
Receive KAIST news by email!
View
Subscribe
Close
Type your e-mail address here.
Subscribe
Close
KAIST
NEWS
유틸열기
홈페이지 통합검색
-
검색
KOREAN
메뉴 열기
Lutein
by recently order
by view order
A KAIST Team Engineers a Microbial Platform for Efficient Lutein Production
<(From Left) Ph.D. Candidate Hyunmin Eun, Distinguished Professor Sang Yup Lee, , Dr. Cindy Pricilia Surya Prabowo> The application of systems metabolic engineering strategies, along with the construction of an electron channeling system, has enabled the first gram-per-liter scale production of lutein from Corynebacterium glutamicum, providing a viable alternative to plant-derived lutein production. A research group at KAIST has successfully engineered a microbial strain capable of producing lutein at industrially relevant levels. The team, led by Distinguished Professor Sang Yup Lee from the Department of Chemical and Biomolecular Engineering, developed a novel C. glutamicum strain using systems metabolic engineering strategies to overcome the limitations of previous microbial lutein production efforts. This research is expected to be beneficial for the efficient production of other industrially important natural products used in food, pharmaceuticals, and cosmetics. Lutein is a xanthophyll carotenoid found in egg yolk, fruits, and vegetables, known for its role in protecting our eyes from oxidative stress and reducing the risk of macular degeneration and cataracts. Currently, commercial lutein is predominantly extracted from marigold flowers; however, this approach has several drawbacks, including long cultivation times, high labor costs, and inefficient extraction yields, making it economically unfeasible for large-scale production. These challenges have driven the demand for alternative production methods. To address these issues, KAIST researchers, including Ph.D. Candidate Hyunmin Eun, Dr. Cindy Pricilia Surya Prabowo, and Distinguished Professor Sang Yup Lee, applied systems metabolic engineering strategies to engineer C. glutamicum, a GRAS (Generally Recognized As Safe) microorganism widely used in industrial fermentation. Unlike Escherichia coli, which was previously explored for microbial lutein production, C. glutamicum lacks endotoxins, making it a safer and more viable option for food and pharmaceutical applications. The team’s work, entitled “Gram-per-litre scale production of lutein by engineered Corynebacterium,” was published in Nature Synthesis on 04 July , 2025. This research details the high-level production of lutein using glucose as a renewable carbon source via systems metabolic engineering. The team focused on eliminating metabolic bottlenecks that previously limited microbial lutein synthesis. By employing enzyme scaffold-based electron channeling strategies, the researchers improved metabolic flux towards lutein biosynthesis while minimizing unwanted byproducts. <Lutein production metabolic pathway engineering> To enhance productivity, bottleneck enzymes within the metabolic pathway were identified and optimized. It was determined that electron-requiring cytochrome P450 enzymes played a major role in limiting lutein biosynthesis. To overcome this limitation, an electron channeling strategy was implemented, where engineered cytochrome P450 enzymes and their reductase partners were spatially organized on synthetic scaffolds, allowing more efficient electron transfer and significantly increasing lutein production. The engineered C. glutamicum strain was further optimized in fed-batch fermentation, achieving a record-breaking 1.78 g/L of lutein production within 54 hours, with a content of 19.51 mg/gDCW and a productivity of 32.88 mg/L/h—the highest lutein production performance in any host reported to date. This milestone demonstrates the feasibility of replacing plant-based lutein extraction with microbial fermentation technology. “We can anticipate that this microbial cell factory-based mass production of lutein will be able to replace the current plant extraction-based process,” said Ph.D. Candidate Hyunmin Eun. He emphasized that the integrated metabolic engineering strategies developed in this study could be broadly applied for the efficient production of other valuable natural products used in pharmaceuticals and nutraceuticals. <Schematic diagram of microbial-based lutein production platform> “As maintaining good health in an aging society becomes increasingly important, we expect that the technology and strategies developed here will play pivotal roles in producing other medically and nutritionally significant natural products,” added Distinguished Professor Sang Yup Lee. This work is supported by the Development of Next-generation Biorefinery Platform Technologies for Leading Bio-based Chemicals Industry project 2022M3J5A1056072 and the Development of Platform Technologies of Microbial Cell Factories for the Next-Generation Biorefineries project 2022M3J5A1056117 from the National Research Foundation supported by the Korean Ministry of Science and ICT. Source: Hyunmin Eun (1st), Cindy Pricilia Surya Prabowo (co-1st), and Sang Yup Lee (Corresponding). “Gram-per-litre scale production of lutein by engineered Corynebacterium”. Nature Synthesis (Online published) For further information: Sang Yup Lee, Distinguished Professor of Chemical and Biomolecular Engineering, KAIST (leesy@kaist.ac.kr, Tel: +82-42-350-3930)
2025.07.14
View 199
Metabolically Engineered Bacterium Produces Lutein
A research group at KAIST has engineered a bacterial strain capable of producing lutein. The research team applied systems metabolic engineering strategies, including substrate channeling and electron channeling, to enhance the production of lutein in an engineered Escherichia coli strain. The strategies will be also useful for the efficient production of other industrially important natural products used in the food, pharmaceutical, and cosmetic industries. Figure: Systems metabolic engineering was employed to construct and optimize the metabolic pathways for lutein production, and substrate channeling and electron channeling strategies were additionally employed to increase the production of the lutein with high productivity. Lutein is classified as a xanthophyll chemical that is abundant in egg yolk, fruits, and vegetables. It protects the eye from oxidative damage from radiation and reduces the risk of eye diseases including macular degeneration and cataracts. Commercialized products featuring lutein are derived from the extracts of the marigold flower, which is known to harbor abundant amounts of lutein. However, the drawback of lutein production from nature is that it takes a long time to grow and harvest marigold flowers. Furthermore, it requires additional physical and chemical-based extractions with a low yield, which makes it economically unfeasible in terms of productivity. The high cost and low yield of these bioprocesses has made it difficult to readily meet the demand for lutein. These challenges inspired the metabolic engineers at KAIST, including researchers Dr. Seon Young Park, Ph.D. Candidate Hyunmin Eun, and Distinguished Professor Sang Yup Lee from the Department of Chemical and Biomolecular Engineering. The team’s study entitled “Metabolic engineering of Escherichia coli with electron channeling for the production of natural products” was published in Nature Catalysis on August 5, 2022. This research details the ability to produce lutein from E. coli with a high yield using a cheap carbon source, glycerol, via systems metabolic engineering. The research group focused on solving the bottlenecks of the biosynthetic pathway for lutein production constructed within an individual cell. First, using systems metabolic engineering, which is an integrated technology to engineer the metabolism of a microorganism, lutein was produced when the lutein biosynthesis pathway was introduced, albeit in very small amounts. To improve the productivity of lutein production, the bottleneck enzymes within the metabolic pathway were first identified. It turned out that metabolic reactions that involve a promiscuous enzyme, an enzyme that is involved in two or more metabolic reactions, and electron-requiring cytochrome P450 enzymes are the main bottleneck steps of the pathway inhibiting lutein biosynthesis. To overcome these challenges, substrate channeling, a strategy to artificially recruit enzymes in physical proximity within the cell in order to increase the local concentrations of substrates that can be converted into products, was employed to channel more metabolic flux towards the target chemical while reducing the formation of unwanted byproducts. Furthermore, electron channeling, a strategy similar to substrate channeling but differing in terms of increasing the local concentrations of electrons required for oxidoreduction reactions mediated by P450 and its reductase partners, was applied to further streamline the metabolic flux towards lutein biosynthesis, which led to the highest titer of lutein production achieved in a bacterial host ever reported. The same electron channeling strategy was successfully applied for the production of other natural products including nootkatone and apigenin in E. coli, showcasing the general applicability of the strategy in the research field. “It is expected that this microbial cell factory-based production of lutein will be able to replace the current plant extraction-based process,” said Dr. Seon Young Park, the first author of the paper. She explained that another important point of the research is that integrated metabolic engineering strategies developed from this study can be generally applicable for the efficient production of other natural products useful as pharmaceuticals or nutraceuticals. “As maintaining good health in an aging society is becoming increasingly important, we expect that the technology and strategies developed here will play pivotal roles in producing other valuable natural products of medical or nutritional importance,” explained Distinguished Professor Sang Yup Lee. This work was supported by the Cooperative Research Program for Agriculture Science & Technology Development funded by the Rural Development Administration of Korea, with further support from the Development of Next-generation Biorefinery Platform Technologies for Leading Bio-based Chemicals Industry Project and by the Development of Platform Technologies of Microbial Cell Factories for the Next-generation Biorefineries Project of the National Research Foundation funded by the Ministry of Science and ICT of Korea.
2022.08.05
View 12037
<<
첫번째페이지
<
이전 페이지
1
>
다음 페이지
>>
마지막 페이지 1